Key Takeaways
- • Accresa Health announced the issuance of its second U.S. patent, No. 12,770,120 B2, which it says further establishes it as the only known DPC technology platform holding issued U.S. patents.
- • The new patent covers affiliate management, healthcare network administration, and payment technology, and joins the company's first U.S. patent, No. 12,682,329 B2.
- • CEO William C. Short said Accresa intends to aggressively enforce its patent rights, including against companies it says are commercializing infringing technology.
- • The announcement was made via Business Wire from Carrollton, Texas, and was issued by the company itself, with no independent verification of the patents' scope or any enforcement action in the release.
Summary
The patent extends Accresa's intellectual property portfolio in affiliate management, healthcare network administration, and payment technology. Together with its first U.S. patent, No. 12,682,329 B2, the filings protect the company's methods for managing complex relationships and financial transactions among employers, healthcare providers, medical groups, and patients.
CEO William C. Short said the company developed the technology over several years of investment and that the new issuance affirms Accresa's ownership of the underlying intellectual property. He said others had attempted to replicate the technology to compete, and stated that the company intends to "aggressively protect our intellectual property" and pursue enforcement, including against companies it says are currently commercializing infringing technology.
The release also restated Accresa's commitment to growing direct primary care, a subscription-based model the company characterizes as central to a better healthcare system. Accresa describes its products as payment and administration solutions for DPC and other subscription-based healthcare models. The release does not name any alleged infringing parties or describe pending litigation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.